NEUREN ’ S VALUE PROPOS I T I ON Realise Neuren’s share of trofinetide value in the US through successful commercialization of DAYBUE Implement commercial strategy for trofinetide exNorth America, using US data for registration Confirm efficacy of NNZ-2591 in Phase 2 trials for 4 valuable indications 1 2 3 Leading pipeline in neurodevelopmental disorders Compound Indication Preclinical Phase 1 Phase 2 Phase 3 Registration Commercial rights Trofinetide Rett North America Rett Rest of World Fragile X NNZ-2591 PhelanMcDermid Angelman Pitt Hopkins Prader-Willi Transforming catalysts in 2023 Three key drivers of future value pharmaceuticals pharmaceuticals pharmaceuticals NA: RoW: Commercial Development Trofinetide Rest of World NNZ-2591 Trofinetide North America ✓ DAYBUE for Rett syndrome approved by FDA ✓ Priority Review Voucher awarded to Acadia • First US commercial sale (end Apr 2023) - US$40mmilestone payment • Quarterly royalties on net sales • Priority Review Voucher value one third share - estimated as US$33m • Commercial partnerships ex-North America for Rett syndrome • Initiate Prader-Willi syndrome Phase 2 trial • Enrolment completion in Phelan-Mcdermid, Pitt Hopkins and Angelman syndromes • Phase 2 trial results, commencing with Phelan-Mcdermid syndrome Neuren Pharmaceuticals Limited Annual Repor t 2022 1
RkJQdWJsaXNoZXIy MjE2NDg3